Aktienanalyse zu BeOne Medicines AG (ONC)ONCBeOne Medicines AG

BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others. It operates in the Healthcare sector.

Beigene, Ltd. appears to be a good buy right now due to its strong financial performance and positive market sentiment. The company has shown a significant increase in revenue, with Q2 2026 revenue reaching $1.7 billion, up from $1.5 billion in Q1 2026. Additionally, the gross margin has improved to 89.76%, indicating efficient cost management. The RSI is at 63.45, suggesting that the stock is in a healthy momentum phase. However, a risk to consider is the recent hedge fund selling activity, which has increased by 7307.41% over the last quarter, indicating potential volatility.